Dr Reddy's Launches Generic Zoledronic Acid Injection in U.S.

New Delhi: Drug firm Dr Reddy's Laboratories said it has launched generic Zoledronic Acid injection used for treating osteoporosis and Paget's disease of bone in the U.S. market following approval from the U.S. health regulator.

The company has launched Zoledronic Acid injection (5 mg/ 100 mL), following approval of its abbreviated new drug application (ANDA) by the U.S. Food & Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement.

The product is generic version of Novartis AG's Reclast injection in the same strength, it added.

"The Reclast brand had total U.S. sales of approximately USD 355 million for the most recent twelve months ending February, 2013 according to IMS Health," Dr Reddy's said.

The company's Zoledronic Acid injection is available in a single use vial for intravenous infusion, it added.

Paget's disease of bone is a chronic disorder that can result in enlarged and misshapen bones.

Shares of Dr Reddy's Laboratories were today trading at 1,888.60 apiece on the BSE in afternoon trade, up 2.93 per cent from their previous close.

Also Read:
Chidambaram Opens BoB's 100th Global Branch in Dubai
Life Insurers' Premium Income Declines 6.12percent during Apr-Feb